Hakan Goker joins Merck Serono VC
This article was originally published in Scrip
Hakan Goker has joined MS Ventures, the corporate venture capital arm of Merck Serono (Merck KGaA), as a director – effective from the 1 November 2013. Prior to joining the Darmstadt, Germany-based firm Dr Goker was acting as a private consultant. He previously worked at Aescap, but left the venture capital company in March this year.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.